Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > TSX promo video ...

<< Previous

Bullboard Posts

Next >>

Post by MrMugsyon Nov 26, 2020 5:55pm

1094 Views

Post# 31985866

TSX promo video ...

Did anyone catch what Dan said about "Fully validating the $30B opportunity" if we solve the problem.

Was he talking specifically about the first drug ?

If so, then he's already communicating the OA, RA and other indications.

-----

https://www.newswire.ca/news-releases/tmx-group-antibe-therapeutics-c-suite-at-the-open-880785937.html

<< Previous

Bullboard Posts

Next >>

Options trading in a volatile macro environment